Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.

The aim of the present study was to compare the antihypertrophic effects of blockade of the renin-angiotensin system (RAS), vasopeptidase inhibition and calcium channel antagonism on cardiac and vascular hypertrophy in diabetic spontaneously hypertensive rats (SHR). SHR with streptozotocin-induced diabetes were treated with one of the following therapies for 32 weeks: the angiotensin-converting enzyme (ACE) inhibitor captopril (100 mg/kg); the angiotensin AT(1) receptor antagonist valsartan (30 mg/kg); a combination of captopril with valsartan; the vasopeptidase inhibitor mixanpril (100 mg/kg); or the calcium channel antagonist amlodipine (6 mg/kg). Systolic blood pressure and cardiac and mesenteric artery hypertrophy were assessed. Mean systolic blood pressure in diabetic SHR (200+/-5 mmHg) was reduced by captopril (162+/-5 mmHg), valsartan (173+/-5 mmHg), mixanpril (176+/-2 mmHg) and amlodipine (159+/-4 mmHg), and was further reduced by the combination of captopril with valsartan (131+/-5 mmHg). Captopril, valsartan and mixanpril reduced heart and left ventricle weights by approx. 10%. The combination of captopril and valsartan further reduced heart weight (-24%) and left ventricular weight (-29%). Amlodipine did not affect cardiac hypertrophy. Only mixanpril and the combination of captopril and valsartan significantly reduced mesenteric weight. The mesenteric wall/lumen ratio was reduced by all drugs, and to a greater extent by the combination of captopril and valsartan. We conclude that optimizing the blockade of vasoconstrictive pathways such as the RAS, particularly with the combination of ACE inhibition and AT(1) receptor antagonism, is associated with antitrophic effects in the context of diabetes and hypertension. In contrast, calcium channel blockade, despite similar effects on blood pressure, confers less antitrophic effects in the diabetic heart and blood vessels.

[1]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[2]  F. Frey,et al.  Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade , 2002, Journal of hypertension.

[3]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[4]  M. Cooper,et al.  Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  M. Cooper,et al.  Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. , 2001, Clinical science.

[6]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[7]  C. Johnston,et al.  Beneficial Renal and Cardiac Effects of Vasopeptidase Inhibition With S21402 in Heart Failure , 2000, Hypertension.

[8]  M. Cooper,et al.  Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury , 2000, Hypertension.

[9]  R. Schrier.  Treating high-risk diabetic hypertensive patients with comorbid conditions. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  C. Johnston,et al.  Optimizing treatment of hypertension in patients with diabetes. , 2000, Journal of the American Medical Association (JAMA).

[11]  C. Johnston,et al.  Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs , 2000, Journal of hypertension.

[12]  Shokei Kim,et al.  Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. , 2000, Hypertension.

[13]  Pickering Tg.  Cardiorenal protection in diabetes. , 2000 .

[14]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[15]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[16]  M. Laakso.  Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. , 1999, Primary care.

[17]  M. Weber,et al.  Emerging treatments for hypertension: potential role for vasopeptidase inhibition. , 1999, American journal of hypertension.

[18]  C. Johnston,et al.  Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. , 1998, Hypertension.

[19]  M. Cooper,et al.  Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin‐diabetes‐associated mesenteric vascular hypertrophy independently of their hypotensive action , 1998, Journal of hypertension.

[20]  M. Gasparo,et al.  Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats , 1998, Journal of hypertension.

[21]  J. Ménard,et al.  Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. , 1997, Circulation.

[22]  C. Johnston,et al.  Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade. , 1996, American journal of hypertension.

[23]  Clark Cm,et al.  Prevention and Treatment of the Complications of Diabetes Mellitus , 1995 .

[24]  M. Cooper,et al.  Diabetes-Associated Mesenteric Vascular Hypertrophy Is Attenuated by Angiotensin-Converting Enzyme Inhibition , 1994, Diabetes.

[25]  J. Schwartz,et al.  Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  M. Fournié-Zaluski,et al.  New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. , 1994, Journal of medicinal chemistry.

[27]  J. Ingelfinger,et al.  Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. , 1993, The American journal of physiology.

[28]  G. Jerums,et al.  Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. , 1992, Kidney international.

[29]  G. Jerums,et al.  Glomerular Filtration Rate in Streptozocin-Induced Diabetic Rats: Role of Exchangeable Sodium, Vasoactive Hormones, and Insulin Therapy , 1990, Diabetes.

[30]  C. Frampton,et al.  Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. , 1990, Hypertension.

[31]  B. Brenner,et al.  Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. , 1987, The Journal of clinical investigation.

[32]  T. Inagami,et al.  Synthetic rat atrial natriuretic factor inhibits in vitro and in vivo renin secretion in rats. , 1985, Endocrinology.

[33]  P. Andrews,et al.  A technique to reduce fixation artifacts to kidney proximal tubules. , 1984, Kidney international.

[34]  C. Johnston,et al.  A review of plasma renin measurements and their clinical significance. , 1971, Australian and New Zealand journal of medicine.

[35]  H. Parving,et al.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. , 2002, Diabetes care.

[36]  M. Cooper,et al.  Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. , 1995, American journal of hypertension.

[37]  C. Clark,et al.  Prevention and treatment of the complications of diabetes mellitus. , 1995, The New England journal of medicine.